Fig. 1 · Structure

Documents & Downloads

Rucaparib (AG-014699) phosphate

Cat. No. A10045 CAS 459868-92-9

PARP inhibitor

AG-014699 (Rucaparib) is a PARP inhibitor that inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair.

In Stock

Publications for Rucaparib (AG-014699) phosphate

2 publications citing this product

  1. Ali Divan, .et al. , Pharmacol Res Perspect, 2020, Apr; 8(2): e00586 PMID: 32342655
  2. Tahira Baloch, .et al. , BMC Cancer, 2019, Jan 10;19(1):44 PMID: 30630446

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Rucaparib phosphate (AG-014699) inhibits PARP activity. In permeabilised D283Med medulloblastoma cells, 0.1, 0.4 and 1 μM inhibited stimulated PARP activity by 81.1%, 96.8% and 97.1%, respectively. These are cell-based enzyme measurements, not a purified-enzyme Ki. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PARP (Cell-free assay) Ki 1.4 nM

Rucaparib (AG-014699) phosphate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Rucaparib (AG-014699) phosphate from 1 published reference. In vitro models include permeabilised human D283Med medulloblastoma cells; human D425Med, D283Med and D384Med medulloblastoma cells.

Rucaparib (AG-014699) phosphate In Vitro Studies

At 0.4 μM, AG-014699 reduced temozolomide GI50 from 807±239 to 42±15 μM in D283Med and from 220±42 to 60±13 μM in D384Med cells (mean±SD, three independent experiments). D425Med cells showed no sensitization. Exposure lasted 5 days for D283Med and 3 days for the other models. [1]

PARP activity in permeabilised D283Med cells

Cell-based study · Permeabilised human D283Med medulloblastoma cells [1]

AG-014699 inhibited stimulated PARP activity relative to DMSO-only controls. This cell-based enzyme assay does not establish a purified-enzyme Ki.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of stimulated PARP activity versus DMSO-only controlPercent inhibition 81.1%, 96.8% and 97.1% at 0.1, 0.4 and 1 μM, respectively; replicate samples n ≥3[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–1 μM; reported results at 0.1, 0.4 and 1 μM
Exposure duration
6-min PAR formation assay; separate pretreatment duration not specified
Method
Permeabilised-cell assay with immunological quantification of poly(ADP-ribose)
Vehicle
DMSO-only control; final DMSO fraction for this assay not specified
Reported limits
No dispersion reported for the three inhibition percentages; replicate samples n ≥3. Pretreatment duration and inhibitor stock solvent not separately stated.
Methods and source locations

Compound reported in the paper: Rucaparib phosphate (AG-014699); Compound label in the paper: AG-014699

Reported experiments with the phosphate salt; no assertion of Adooq lot validation.

Materials and methods: Materials; Methods: Inhibition of cellular PARP activity by AG-014699; Results: AG-014699 and PARP-1 inhibition in permeabilised medulloblastoma cells

Inhibition of stimulated PARP activity versus DMSO-only control: PAR immunodetection using 10H antibody and a PAR standard curve — Methods: Inhibition of cellular PARP activity by AG-014699; Results: AG-014699 and PARP-1 inhibition in permeabilised medulloblastoma cells

Temozolomide growth inhibition with AG-014699

Cell-based study · Human D425Med, D283Med and D384Med medulloblastoma cells [1]

Adding 0.4 μM AG-014699 lowered temozolomide GI50 in D283Med and D384Med cells but did not sensitize D425Med cells. AG-014699 alone was reported not to inhibit growth at 0.4 μM (data not shown).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
D425MED temozolomide growth inhibitionTemozolomide GI50 9.3±7.5 μM alone; 13.3±3.2 μM with AG-014699; mean±SD, three independent experiments[1]
D283MED temozolomide growth inhibitionTemozolomide GI50 807±239 μM alone; 42±15 μM with AG-014699; P=0.005; mean±SD, three independent experiments[1]
D384MED temozolomide growth inhibitionTemozolomide GI50 220±42 μM alone; 60±13 μM with AG-014699; P=0.003; mean±SD, three independent experiments[1]

Literature-Reported Treatment Conditions

Treatment concentration
AG-014699: 0.4 μM; varying temozolomide concentrations
Exposure duration
Continuous exposure for 3 days (D425Med, D384Med) or 5 days (D283Med), approximately three cell divisions
Method
XTT growth assay; GI50 from fitted concentration-response curves
Vehicle
Temozolomide added in DMSO, final 0.5% (v/v); DMSO or AG-014699-alone controls
Co-treatment
Temozolomide with or without 0.4 μM AG-014699
Reported limits
AG-014699 stock solvent is not separately specified. The complete temozolomide concentration series is not reproduced here.
Methods and source locations

Compound reported in the paper: Rucaparib phosphate (AG-014699); Compound label in the paper: AG-014699

Reported experiments with the phosphate salt; no assertion of Adooq lot validation.

Materials and methods: Materials; Methods: In vitro growth inhibition and cytotoxicity assays; Results: Potentiation of temozolomide induced growth inhibition by AG-014699; Table 1

D425MED temozolomide growth inhibition: XTT; comparison with temozolomide alone by two-tailed Student’s t-test where P is reported — Table 1 (GI50 columns and footnote); Methods: In vitro growth inhibition and cytotoxicity assays

D283MED temozolomide growth inhibition: XTT; comparison with temozolomide alone by two-tailed Student’s t-test where P is reported — Table 1 (GI50 columns and footnote); Methods: In vitro growth inhibition and cytotoxicity assays

D384MED temozolomide growth inhibition: XTT; comparison with temozolomide alone by two-tailed Student’s t-test where P is reported — Table 1 (GI50 columns and footnote); Methods: In vitro growth inhibition and cytotoxicity assays

Rucaparib (AG-014699) phosphate In Vivo Studies

In subcutaneous medulloblastoma xenografts, AG-014699 (1 mg kg−1 i.p.) plus temozolomide (68 mg kg−1 orally), daily for 5 days, produced model-dependent effects. D283Med growth delay changed only from 2 to 2.5 days. D384Med growth delay increased from 28.5 to 46 days, but this difference was not significant (P=0.11). Combination treatment increased body-weight loss relative to temozolomide alone. [1]

AG-014699 with temozolomide in medulloblastoma xenografts

Animal study · Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group [1]

Combination efficacy varied by model. D283Med showed little additional growth delay despite cellular sensitization. In D384Med, growth delay increased from 28.5 to 46 days, but the combination benefit was not statistically significant (P=0.11). AG-014699 alone did not materially suppress tumor growth at the tested schedule.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Treatment-associated body-weight lossWeight loss Temozolomide 5±4%; AG-014699 1±1%; combination 10±6%. Combination versus temozolomide P=0.013. The ± statistic is not defined in this Results passage.[1]

Conditions shared by the study groups

Frequency
Once daily
Treatment course
5 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline controlNormal saline; single-agent comparators includedMedian time to RTV4: D425Med 19 days; D283Med 7 days; D384Med 16 days. Complete regressions in Table 2: 0/5 for each model.[1]
AG-014699 alone
1 mg kg−1
Normal saline; single-agent comparators includedMedian time to RTV4: D425Med 15.5 days; D283Med 8 days; D384Med 20 days. Complete regressions: 0/5 for each model.[1]
Temozolomide alone
68 mg kg−1
Normal saline; single-agent comparators includedMedian time to RTV4: D425Med >100 days; D283Med 9 days; D384Med 44.5 days. Tumor growth delay: >81, 2 and 28.5 days, respectively. Table 2 complete regressions: 2/5, 0/5 and 1/5.[1]
AG-014699 plus temozolomide
AG-014699 1 mg kg−1 plus temozolomide 68 mg kg−1
Normal saline; single-agent comparators includedMedian time to RTV4: D425Med >100 days; D283Med 9.5 days; D384Med 62 days. Tumor growth delay: >81, 2.5 and 46 days, respectively. Table 2 complete regressions: 3/5, 0/5 and 1/5. D384Med incremental benefit: P=0.11, Mann–Whitney test.[1]
Saline control
Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
Vehicle: Normal saline
Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
AG-014699 alone
Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
Route: Intraperitoneal
Vehicle: AG-014699 vehicle not separately specified
Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
Temozolomide alone
Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
Route: Oral
Vehicle: Temozolomide in saline
Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
AG-014699 plus temozolomide
Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
Route: AG-014699 intraperitoneal; temozolomide oral
Vehicle: AG-014699 vehicle not separately specified
Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
Methods and source locations

Compound reported in the paper: Rucaparib phosphate (AG-014699); Compound label in the paper: AG-014699

Reported experiments with the phosphate salt; no assertion of Adooq lot validation.

Materials and methods: Materials; Methods: Establishment of D425Med, D283Med and D384Med tumour xenografts; Tumour growth inhibition in vivo; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts; Table 2

Treatment-associated body-weight loss: Body-weight monitoring; unpaired t-test — Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts, final paragraph

Saline control · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts

AG-014699 alone · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts

Temozolomide alone · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts

AG-014699 plus temozolomide · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 459868-92-9
Applications PARP inhibitor
Formula C19H18FN3O.H3PO4
Molecular Weight 421.4
Synonyms PF-01367338; AG-014447 (as free base)
SMILES
CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)N2)F.OP(=O)(O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 81 mg/mL (192.23 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rucaparib (AG-014699) phosphate Research References

  1. [1] Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British journal of cancer (2010). PMID: 20978505 DOI: 10.1038/sj.bjc.6605946 Source material

Publications

2 publications citing this product

  1. Ali Divan, .et al. , Pharmacol Res Perspect, 2020, Apr; 8(2): e00586 PMID: 32342655
  2. Tahira Baloch, .et al. , BMC Cancer, 2019, Jan 10;19(1):44 PMID: 30630446
Press to skip carousel

You May Also Consider

A-966492

A10019 CAS 934162-61-5

A-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
The price depends on the options chosen on the product page

Starting at $20.00

View Sizes
Veliparib

A10026 CAS 912444-00-9

ABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
AG14361

A10046 CAS 328543-09-5

AG14361 is a potent PARP inhibitor, enhanced TMZ cytotoxicity in MMR(mismatch repair)-proficient / deficient cells.
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
Olaparib

A10111 CAS 763113-22-0

Olaparib (AZD2281) is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
Iniparib

A10164 CAS 160003-66-7

BSI-201 is a potent inhibitor of PARP-1 and has been shown to cross the blood-brain barrier.
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
3-Aminobenzamide

A10475 CAS 3544-24-9

3-Aminobenzamide is a novel PARP inhibitor, known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage.
The price depends on the options chosen on the product page

Starting at $20.00

View Sizes
XAV 939

A10994 CAS 284028-89-3

XAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 μM for TNKS1 and TNKS2 respectively).
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
Niraparib

A11026 CAS 1038915-60-4

MK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
The price depends on the options chosen on the product page

Starting at $50.00

View Sizes

Added to your cart

View Cart Checkout
Loading...